Show simple item record

dc.contributor.authorGallagher, C. T.
dc.contributor.authorAssi, S.
dc.contributor.authorStair, J. L.
dc.contributor.authorFergus, S.
dc.contributor.authorCorazza, Ornella
dc.contributor.authorCorkery, John
dc.contributor.authorSchifano, Fabrizio
dc.date.accessioned2012-08-15T14:01:06Z
dc.date.available2012-08-15T14:01:06Z
dc.date.issued2012-03-01
dc.identifier.citationGallagher , C T , Assi , S , Stair , J L , Fergus , S , Corazza , O , Corkery , J & Schifano , F 2012 , ' 5,6-Methylenedioxy-2-aminoindane : from laboratory curiosity to 'legal high' ' , Human Psychopharmacology , vol. 27 , no. 2 , pp. 106-112 . https://doi.org/10.1002/hup.1255
dc.identifier.issn1099-1077
dc.identifier.otherPURE: 668827
dc.identifier.otherPURE UUID: 138cb300-374a-4258-969c-ca1f68615fa0
dc.identifier.otherPubMed: 22389075
dc.identifier.otherScopus: 84858022275
dc.identifier.otherORCID: /0000-0002-7134-0665/work/70189317
dc.identifier.urihttp://hdl.handle.net/2299/8835
dc.descriptionMEDLINE® is the source for the MeSH terms of this document.
dc.description.abstractThe fully synthetic 'legal high' 5,6-methylenedioxy-2-aminoindane (MDAI) is an analogue of 3,4-methylenedioxymethamphetamine. Although developed in the 1990s, it was not widely abused until 2010. However, mephedrone was banned in the UK in April 2010, and almost immediately, MDAI was widely advertised as a legal alternative. This paper provides both an overview of the current state of knowledge of MDAI and a critical analysis of online available information relating to its psychoactive effects, adverse reactions and use in combination with other drugs.en
dc.format.extent7
dc.language.isoeng
dc.relation.ispartofHuman Psychopharmacology
dc.title5,6-Methylenedioxy-2-aminoindane : from laboratory curiosity to 'legal high'en
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionLaw, Ethics and Professsionalism in Pharmacy Practice
dc.contributor.institutionMedicinal and Analytical Chemistry
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionNanopharmaceutics
dc.contributor.institutionNatural Product Chemistry and Drug Design
dc.contributor.institutionPharmacy Education
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionCentre for Postgraduate Medicine
dc.contributor.institutionPostgraduate Medicine
dc.contributor.institutionHealth Services and Medicine
dc.contributor.institutionPublic Health
dc.contributor.institutionPrescription and Illicit Drug Misuse
dc.contributor.institutionPatient and Medicines Safety
dc.contributor.institutionDepartment of Pharmacy, Pharmacology and Postgraduate Medicine
dc.description.statusPeer reviewed
rioxxterms.versionofrecordhttps://doi.org/10.1002/hup.1255
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record